Altimmune CBO exercises 14,600 RSUs, withholds tax

Altimmune, Inc. Chief Business Officer Raymond M. Jordt reported an RSU vesting and related tax withholding transaction.

Rhea-AI Filing Summary

Altimmune, Inc. Chief Business Officer Raymond M. Jordt reported an RSU vesting and related tax withholding transaction. On January 25, 2026, 14,600 Restricted Stock Units were converted into an equal number of Altimmune common shares at an exercise price of $0.

On the same date, 3,855 common shares were surrendered to Altimmune at $5.5 per share to cover taxes due on the RSU vesting. After these transactions, Jordt directly held 53,915 shares of common stock and 29,200 RSUs. The RSUs vest in substantially equal annual installments over four years following January 25, 2024, contingent on continued service.

Insider Trade Summary

14,600 shares exercised/converted

Exercise 3 txns

Insider Jordt Raymond M

Role Chief Business Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	14,600	$0.00	$0.00
Exercise	Common Stock, par value $0.0001	14,600	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock, par value $0.0001	3,855	$5.50	$21K

Holdings After Transaction: Restricted Stock Units — 29,200 contracts (Direct); Common Stock, par value $0.0001 — 53,915 shares (Direct)

Footnotes (3)

1. F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
2. F2. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
3. F3. The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Altimmune (ALT) report for Raymond M. Jordt?

Altimmune reported that Chief Business Officer Raymond M. Jordt had 14,600 Restricted Stock Units convert into the same number of common shares on January 25, 2026, followed by a tax withholding share surrender.

How many Altimmune RSUs vested for the Chief Business Officer on January 25, 2026?

On January 25, 2026, 14,600 RSUs held by the Chief Business Officer vested and were settled into 14,600 shares of Altimmune common stock at an exercise price of $0.

How many Altimmune shares were surrendered to cover taxes on the RSU vesting?

The filing states that 3,855 shares of Altimmune common stock were surrendered to the issuer at $5.5 per share solely to satisfy tax obligations related to the RSU vesting.

What are Raymond M. Jordt’s Altimmune share and RSU holdings after this Form 4 transaction?

Following the reported transactions, the Chief Business Officer directly held 53,915 shares of Altimmune common stock and 29,200 Restricted Stock Units, as disclosed.

How do the Altimmune RSUs for the Chief Business Officer vest over time?

The RSUs vest in substantially equal annual installments over four years following January 25, 2024, subject to the reporting person’s continued service, and they have no expiration date.

Were the Altimmune shares sold on the open market in this Form 4?

No. The filing explains that the 3,855 shares were surrendered to the issuer solely to cover taxes associated with the vesting of RSUs, rather than sold in an open-market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 07:10 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jordt Raymond M

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001	01/25/2026		M		14,600	A	$0(1)	57,770	D
Common Stock, par value $0.0001	01/25/2026		F(2)		3,855	D	$5.5	53,915	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/25/2026		M			14,600	(3)	(3)	Common Stock, par value $0.0001	14,600	$0	29,200	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

2. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.

3. The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

	/s/ Gregory Weaver, as Attorney-in-Fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.